October 2014 Issue of The Ophthalmologist

Why are most of the speakers at congresses – and the vast majority of industry leaders – men?

Transgenic mouse studies have revealed a signaling pathway that’s central to Schlemm’s canal formation

Statins may interfere with glucose metabolism, and their use might be damaging the diabetic eye. Or perhaps not...

Ophthalmologists would change recommendations if treating themselves

Survey shows UK-based GPs lack confidence in their ability to diagnose ocular disease

Alimera and Allergan benefit from new FDA approvals, Allergan continues to battle Valeant, and Oculentis sues Lenstec over IOL patent infringement

The world’s top clinicians and captains of industry came together in London last month to discuss the future of ophthalmology. Here’s what we learned

Showcasing the greatest ophthalmic advances of the year

Fusing the embryos of mice, where one contains a marker of its lineage, is a well-established technique in developmental biology research. The stripy corneas were still a surprise, though…

Anti-VEGF agents are effective in treating DME – but not always indefinitely. Steroids work – but accelerate cataract development.

New intraocular lenses offer extended depth of focus, but this can come at a cost: glares, halos and comets. Can these be designed away?

What does analysis of the last five years of the literature on vitreomacular traction/ adhesion tell us about the priorities of the field and the major contributors to it?

Five tips to ensure patients’ expectations of vision following cataract surgery are grounded in reality.

Peer reviewers should insist that tricky statistical techniques are explained clearly to non-statisticians.

Mark Latina recounts his story of the invention of selective laser trabeculoplasty (SLT).

Sitting Down With… Charles McGhee, Director of the New Zealand National Eye Centre, University of Auckland, New Zealand.